在接受阿片类药物维持治疗的患者中，从基线到 1 年随访期间，自我报告躯体症状的变化。

Change in self-reported somatic symptoms among patients in opioid maintenance treatment from baseline to 1-year follow-up.

机构信息

Addiction Unit, Sørlandet Hospital HF, Po. box 416, Kristiansand, Norway.

Norwegian Centre for Addiction Research (SERAF), University of Oslo, Kirkeveien 166, N-0407, Oslo, Norway.

出版信息

BMC Psychiatry. 2024 Feb 21;24(1):149. doi: 10.1186/s12888-024-05590-w.

DOI:10.1186/s12888-024-05590-w

PMID:38383345

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10882792/

Abstract

BACKGROUND

High somatic comorbidity is common among patients in treatment for opioid use disorder (OUD). The present study aims to investigate changes in self-reported somatic health conditions and somatic symptoms among patients entering opioid maintenance treatment (OMT) programs.

METHODS

We used data from the Norwegian Cohort of Patients in OMT and Other Drug Treatment (NorComt) study. Of 283 patients who entered OMT, 176 were included for analysis at a 1-year follow-up. Participants provided self-reported data during structured interviews on somatic conditions, somatic symptoms, substance use severity measures, and mental distress. A multivariable linear regression analysis identified factors associated with changes in the burden of somatic symptoms.

RESULTS

Patients entering OMT reported a high prevalence of somatic conditions at the beginning of treatment, with 3 of 5 patients reporting at least one. The most prevalent condition was hepatitis C, followed by asthma and high blood pressure. Patients reported experiencing a high number of somatic symptoms. The intensity of these symptoms varied across a wide spectrum, with oral health complaints and reduced memory perceived as the most problematic. Overall, for the entire sample, there was no significant change in somatic symptoms from baseline to 1 year. Further analysis indicated that those who reported a higher burden of somatic symptoms at baseline had the greatest improvement at the 1-year follow-up. A higher number of somatic conditions and higher mental distress at baseline was associated with improvements in somatic symptoms burden at follow-up.

CONCLUSIONS

Patients in OMT report a range of somatic conditions and somatic symptoms. Given the wide range of symptoms reported by patients in OMT, including some at high intensity levels, healthcare providers should take into consideration the somatic healthcare needs of individuals in OMT populations.

CLINICAL TRIAL REGISTRATION

Clinicaltrials.gov no. NCT05182918. Registered 10/01/2022 (the study was retrospectively registered).

摘要

背景

接受阿片类药物使用障碍（OUD）治疗的患者常伴有较高的躯体共病。本研究旨在调查进入阿片类药物维持治疗（OMT）项目的患者的自我报告躯体健康状况和躯体症状的变化。

方法

我们使用了来自挪威 OMT 和其他药物治疗患者队列研究（NorComt）的数据。在 283 名进入 OMT 的患者中，有 176 名在 1 年随访时进行了分析。参与者在结构化访谈中提供了关于躯体疾病、躯体症状、物质使用严重程度测量和精神困扰的自我报告数据。多变量线性回归分析确定了与躯体症状负担变化相关的因素。

结果

进入 OMT 的患者在治疗开始时报告了较高的躯体疾病患病率，每 5 名患者中就有 3 名报告了至少一种疾病。最常见的疾病是丙型肝炎，其次是哮喘和高血压。患者报告了较多的躯体症状。这些症状的强度范围广泛，口腔健康问题和记忆力减退被认为是最严重的问题。总体而言，对于整个样本，从基线到 1 年，躯体症状没有显著变化。进一步分析表明，基线时躯体症状负担较高的患者在 1 年随访时改善最大。基线时躯体疾病数量较多和精神困扰较高与随访时躯体症状负担的改善相关。